Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Metz

Showing results (181-190 of 258) with videos related to

Pageof 26
Sort By:
The British Journal of Dermatology|February 3, 2024
Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trialEva Grekowitz, Martin Metz, Sabine Altrichter, et al.
Allergy|August 26, 2021
Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet needAram Antó, Rasmus Maurer, Ana Gimenez-Arnau, et al.
Nature|November 16, 2004
Mast cells promote homeostasis by limiting endothelin-1-induced toxicityMarcus Maurer, Jochen Wedemeyer, Martin Metz, et al.
The Journal of Allergy and Clinical Immunology. Global|March 19, 2026
Dupilumab in patients with cold urticaria: Results from a phase 3 trialMartin Metz, Sarbjit S Saini, Akiko Yagami, et al.
Frontiers in Immunology|November 29, 2023
In the skin lesions of patients with mycosis fungoides, the number of MRGPRX2-expressing cells is increased and correlates with mast cell numbersMan Hu, Polina Pyatilova, Sabine Altrichter, et al.
Allergy|August 5, 2018
Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumabKarsten Weller, Tatevik Ohanyan, Tomasz Hawro, et al.
Journal of the American Academy of Dermatology|August 21, 2025
Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single-dose studyMartin Metz, Sonja Ständer, Ali Moiin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2025
Depletion of mast cells with barzolvolimab, an anti-KIT antibody, does not affect mast cell progenitorsSherezade Moñino-Romero, Niklas Amadeus Mahnke, Dorothea Terhorst-Molawi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 28, 2026
Differential susceptibility of hair colour changes after barzolvolimabMelba Muñoz, Jimmy Zhou, Hanna Bonnekoh, et al.
Journal of the American Academy of Dermatology|June 6, 2025
Human papillomavirus infection increases risk of new-onset prurigo nodularis: A multicenter retrospective cohort study using global and US electronic medical records of TriNetX networkShuo-Yan Gau, Shao-Wei Lo, Yung-Fang Tu, et al.
Pageof 26

Showing results (181-190 of 258) with videos related to

Sort By:
Pageof 26
The British Journal of Dermatology|February 3, 2024
Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trialEva Grekowitz, Martin Metz, Sabine Altrichter, et al.
Allergy|August 26, 2021
Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet needAram Antó, Rasmus Maurer, Ana Gimenez-Arnau, et al.
Nature|November 16, 2004
Mast cells promote homeostasis by limiting endothelin-1-induced toxicityMarcus Maurer, Jochen Wedemeyer, Martin Metz, et al.
The Journal of Allergy and Clinical Immunology. Global|March 19, 2026
Dupilumab in patients with cold urticaria: Results from a phase 3 trialMartin Metz, Sarbjit S Saini, Akiko Yagami, et al.
Frontiers in Immunology|November 29, 2023
In the skin lesions of patients with mycosis fungoides, the number of MRGPRX2-expressing cells is increased and correlates with mast cell numbersMan Hu, Polina Pyatilova, Sabine Altrichter, et al.
Allergy|August 5, 2018
Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumabKarsten Weller, Tatevik Ohanyan, Tomasz Hawro, et al.
Journal of the American Academy of Dermatology|August 21, 2025
Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single-dose studyMartin Metz, Sonja Ständer, Ali Moiin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2025
Depletion of mast cells with barzolvolimab, an anti-KIT antibody, does not affect mast cell progenitorsSherezade Moñino-Romero, Niklas Amadeus Mahnke, Dorothea Terhorst-Molawi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 28, 2026
Differential susceptibility of hair colour changes after barzolvolimabMelba Muñoz, Jimmy Zhou, Hanna Bonnekoh, et al.
Journal of the American Academy of Dermatology|June 6, 2025
Human papillomavirus infection increases risk of new-onset prurigo nodularis: A multicenter retrospective cohort study using global and US electronic medical records of TriNetX networkShuo-Yan Gau, Shao-Wei Lo, Yung-Fang Tu, et al.
Pageof 26